Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neuroendocrine Tumors 40Gastro-enteropancreatic neuroendocrine tumor 8Paraganglioma 6Meningioma 6Pheochromocytoma 5Carcinoma, Neuroendocrine 4Neuroblastoma 3Carcinoid Tumor 3Adenoma, Islet Cell 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasms, Germ Cell and Embryonal 2Neoplasms 2Medulloblastoma 2Glioma 2Glioblastoma 2Ependymoma 2Carcinoma, Merkel Cell 2Carcinoma, Medullary 2Stomach Neoplasms 1Somatostatinoma 1Somatostatin Receptor-positive Neuroendocrine Tumor 1Somatostatin Receptor-positive GEP-NET 1Small Cell Lung Carcinoma 1Serotonin Syndrome 1Sarcoma, Synovial 1Recurrence 1Pituitary Neoplasms 1Parathyroid Neoplasms 1Pancreatic Diseases 1

Interventions

Etoposide 10Cisplatin 7Carboplatin 6tislelizumab 2camrelizumab 2atezolizumab 2anlotinib 2Topotecan 2Irinotecan 2Drug Therapy 2Bevacizumab 2temsirolimus 1spartalizumab 1oblimersen 1obinutuzumab 1lutetium Lu 177 dotatate 1gossypol acetic acid 1durvalumab 1ceralasertib 1apatinib 1Temozolomide 1Sirolimus 1Podophyllotoxin 1Platinum 1Paclitaxel 1NVP-BKM120 1Injections 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1EC regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Extensive Stage Small Cell Lung Cancer × lutetium Lu 177 dotatate × Clear all
NCT05142696 2026-05-29

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

Novartis

Phase 1/2 Active not recruiting
24 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡